Diebold Nixdorf Statistics
Total Valuation
DBD has a market cap or net worth of $1.20 billion. The enterprise value is $3.61 billion.
Market Cap | 1.20B |
Enterprise Value | 3.61B |
Important Dates
The next confirmed earnings date is Thursday, May 2, 2024, before market open.
Earnings Date | May 2, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
DBD has 37.57 million shares outstanding.
Shares Outstanding | 37.57M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 12.47 |
PS Ratio | 0.35 |
Forward PS | 0.32 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 1.03 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.04
Current Ratio | 1.04 |
Quick Ratio | 0.51 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -0.67 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -16.60% |
Return on Capital (ROIC) | -11.14% |
Revenue Per Employee | $166,143 |
Profits Per Employee | -$24,257 |
Employee Count | 21,000 |
Asset Turnover | 1.14 |
Inventory Turnover | 4.30 |
Taxes
In the past 12 months, DBD has paid $119.40 million in taxes.
Income Tax | 119.40M |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (1Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 33.70 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 43.56 |
Average Volume (30 Days) | 145,700 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DBD had revenue of $3.49 billion and -$509.40 million in losses. Loss per share was -$6.43.
Revenue | 3.49B |
Gross Profit | 781.30M |
Operating Income | -130.40M |
Pretax Income | -390.00M |
Net Income | -509.40M |
EBITDA | -34.60M |
EBIT | -157.00M |
Loss Per Share | -$6.43 |
Balance Sheet
The company has $263.00 million in cash and $2.66 billion in debt, giving a net cash position of -$2.39 billion or -$63.68 per share.
Cash & Cash Equivalents | 263.00M |
Total Debt | 2.66B |
Net Cash | -2.39B |
Net Cash Per Share | -$63.68 |
Equity / Book Value | -1.49B |
Book Value Per Share | -39.54 |
Working Capital | 66.30M |
Cash Flow
In the last 12 months, operating cash flow was -$257.60 million and capital expenditures -$52.60 million, giving a free cash flow of -$310.20 million.
Operating Cash Flow | -257.60M |
Capital Expenditures | -52.60M |
Free Cash Flow | -310.20M |
FCF Per Share | -$3.91 |
Margins
Gross margin is 22.39%, with operating and profit margins of -3.74% and -14.60%.
Gross Margin | 22.39% |
Operating Margin | -3.74% |
Pretax Margin | -11.18% |
Profit Margin | -14.60% |
EBITDA Margin | -0.99% |
EBIT Margin | -4.50% |
FCF Margin | -8.89% |
Dividends & Yields
DBD does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.76% |
Shareholder Yield | -0.76% |
Earnings Yield | -41.97% |
FCF Yield | -25.56% |
Analyst Forecast
The average price target for DBD is $34.50, which is 7.71% higher than the current price. The consensus rating is "Buy".
Price Target | $34.50 |
Price Target Difference | 7.71% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
DBD has an Altman Z-Score of 0.46 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.46 |
Piotroski F-Score | 2 |